Immune checkpoint inhibitor–associated hypercalcaemia. Issue 9 (29th December 2020)

• Record Type: Journal Article
• Authors: Izzedine, Hassan; Chazal, Thibaud; Wanchoo, Rimda; Jhaveri, Kenar D
• Is Part Of: Nephrology dialysis transplantation. Volume 37:Issue 9(2022)
• Page Start: 1598
• Page End: 1608
• Publication Date: 2020-12-29
• Subjects: anti-CTLA4 antibodies -- hypercalcaemia -- PTHrp -- programmed cell death-1 -- programmed cell death-ligand 1; Nephrology -- Periodicals; Hemodialysis -- Periodicals; Kidneys -- Transplantation -- Periodicals; Hemodialysis; Kidneys -- Transplantation; Nephrology; Periodicals; 616.61
• DOI: 10.1093/ndt/gfaa326
• Languages: English
• ISSNs: 0931-0509

Abstract

Abstract: Immune checkpoint inhibitors (CPIs) have recently become a cornerstone for the treatment of different advanced cancers. These drugs have the ability to reactivate the immune system against tumour cells but can also trigger a myriad of side effects, termed immune-related adverse events (irAEs). Although there are numerous reports of CPI-related endocrinopathies, hypercalcaemia as a suspected irAE is not well documented. The mechanisms of CPI hypercalcaemia are not clearly established. However, in our review, four distinct causes emerged: endocrine disease-related, sarcoid-like granuloma, humoral hypercalcaemia due to parathyroid-related hormone and hyperprogressive disease following CPI initiation. Prompt recognition of hypercalcaemia and the institution of therapy can be lifesaving, affording the opportunity to address the underlying aetiology. In this review we discuss the incidence, diagnosis and management of immune-related hypercalcaemia in oncological patients receiving CPI agents.